glp-1 news today october 23 2025 obesity drug 21 Perspectives from employers on the costs and issues associated with covering agonists for weight loss Eli Lilly to seek approval – Alarming rise in weight loss

At 24 h post-treated, cell viability was determined and 30% inhibitory concentration (IC 30 ) of AFB 1 was calculated

Many patients describe it as the constant "food noise" finally quieting down

Theanine c bit l c nh hng n hot ng dopaminergic v serotonergic

Ictericia neonatal

States can opt into discounted GLP1 pricing for Medicaid starting in 2026 under new negotiated pricing, potentially easing cost barriers and encouraging broader adoption

Purpose-built for physicians GLP-1 agents can help lower systemic inflammation, show promise in rheumatology The apparent success and now almost ever-present ubiquity of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, including those under rheumatology umbrella